Julie Martyn
About
Julie Martyn is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology.
According to data from OpenAlex, Julie Martyn has authored 23 papers receiving a total of 767 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Reproductive Medicine, 7 papers in Obstetrics and Gynecology and 6 papers in Oncology. Recurrent topics in Julie Martyn's work include Ovarian cancer diagnosis and treatment (12 papers), Endometrial and Cervical Cancer Treatments (7 papers) and Childhood Cancer Survivors' Quality of Life (4 papers). Julie Martyn is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), Endometrial and Cervical Cancer Treatments (7 papers) and Childhood Cancer Survivors' Quality of Life (4 papers). Julie Martyn collaborates with scholars based in Australia, United States and New Zealand. Julie Martyn's co-authors include Stephen E. Alway, Parco M. Siu, Randall W. Bryner, John J. Bass, Michael Friedländer, Ferenc Jeanplong, Michael P. Spiller, Mark Thomas, Ravi Kambadur and Linda Mileshkin and has published in prestigious journals such as Journal of Clinical Oncology, Molecular and Cellular Biology and The FASEB Journal.
In The Last Decade
Julie Martyn
23 papers receiving 750 citations
Peers
Julie Martyn
Vanessa Ramírez United States
Feihong Luo China
Teoman Akçay Türkiye
Brian C. Cooper United States
Shigeo Akira Japan
Julie M. Carroll United States
Giovanna Municchi Italy
Talat Mushtaq United Kingdom
Keshav Kumar Gupta United Kingdom
Citations per year, relative to Julie Martyn Julie Martyn (= 1×)
peers
Vanessa Ramírez
Countries citing papers authored by Julie Martyn
Since
Specialization
Citations
This map shows the geographic impact of Julie Martyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Martyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Martyn more than expected).
Fields of papers citing papers by Julie Martyn
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Julie Martyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Martyn. The network helps show where Julie Martyn may publish in the future.
Co-authorship network of co-authors of Julie Martyn
This figure shows the co-authorship network connecting the top 25 collaborators of Julie Martyn. A scholar is included among the top collaborators of Julie Martyn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Martyn. Julie Martyn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Martyn, Julie, et al.. (2021). Exploring the attitudes, beliefs, and values of the long-term care workforce towards palliative care: A qualitative evidence synthesis protocol. Progress in Palliative Care. 30(2). 94–100.
2.
Lindemann, Kristina, Philip Beale, Emma Rossi, et al.. (2018). Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). Cancer Chemotherapy and Pharmacology. 83(1). 97–105.
3.
O’Connell, Rachel, Philip Beale, Orla McNally, et al.. (2017). Paragon (ANZGOG-0903). International Journal of Gynecological Cancer. 27(5). 900–906.
4.
King, Madeleine, Martin R. Stockler, Phyllis Butow, et al.. (2014). Development of the Measure of Ovarian Symptoms and Treatment Concerns. International Journal of Gynecological Cancer. 24(5). 865–873.
5.
Mileshkin, Linda, Kailash Narayan, Kathleen N. Moore, et al.. (2014). A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).. Journal of Clinical Oncology. 32(15_suppl). TPS5632–TPS5632.
6.
Friedländer, Michael, Martin R. Stockler, Rachel O’Connell, et al.. (2014). Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer. International Journal of Gynecological Cancer. 24(5). 857–864.
7.
Friedländer, Michael, Martin R. Stockler, Phyllis Butow, et al.. (2014). Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/ GCIG/PoCoG).. Journal of Clinical Oncology. 32(15_suppl). TPS5615–TPS5615.
8.
Rischin, Danny, Philip Beale, Emma Rossi, et al.. (2014). A phase I study of the vascular-disrupting agent BNC105P in combination with gemcitabine-carboplatin in platinum-sensitive ovarian cancer patients in first or second relapse.. Journal of Clinical Oncology. 32(15_suppl). 5524–5524.
9.
Sjoquist, Katrin Marie, Michael Friedländer, Linda Mileshkin, et al.. (2014). The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.. Journal of Clinical Oncology. 32(15_suppl). TPS5627–TPS5627.
10.
Martyn, Julie, et al.. (2013). Exploring the relationships between teaching, approaches to learning and critical thinking in a problem-based learning foundation nursing course. Nurse Education Today. 34(5). 829–835.
11.
Martyn, Julie, et al.. (2013). Distance and devices — Potential barriers to use of wireless handheld devices. Nurse Education Today. 34(3). 457–461.
12.
Friedländer, Michael, Katrin Marie Sjoquist, Dirkje W. Sommeijer, et al.. (2013). PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.. Journal of Clinical Oncology. 31(15_suppl). TPS5614–TPS5614.
13.
Blinman, Prunella, Mark W. Donoghoe, Julie Martyn, et al.. (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology. 24(4). 359–359.
14.
Sjoquist, Katrin Marie, Michael Friedländer, Rachel O’Connell, et al.. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study. The Oncologist. 18(11). 1221–1228.
15.
Mileshkin, Linda, Kailash Narayan, Kathleen N. Moore, et al.. (2012). A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.. Journal of Clinical Oncology. 30(15_suppl). TPS5116–TPS5116.
16.
Sjoquist, Katrin Marie, Julie Martyn, Richard J. Edmondson, & Michael Friedländer. (2011). The Role of Hormonal Therapy in Gynecological Cancers—Current Status and Future Directions. International Journal of Gynecological Cancer. 21(7). 1328–1333.
17.
Friedländer, Michael, Phyllis Butow, Martin R. Stockler, et al.. (2009). Symptom Control in Patients With Recurrent Ovarian Cancer. International Journal of Gynecological Cancer. 19. S44–S48.
18.
Martyn, Julie, John J. Bass, & Jenny M. Oldham. (2004). Skeletal muscle development in normal and double‐muscled cattle. The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology. 281A(2). 1363–1371.
19.
Siu, Parco M., Randall W. Bryner, Julie Martyn, & Stephen E. Alway. (2004). Apoptotic adaptations from exercise training in skeletal and cardiac muscles. The FASEB Journal. 18(10). 1150–1152.
20.
Spiller, Michael P., Ravi Kambadur, Ferenc Jeanplong, et al.. (2002). The Myostatin Gene Is a Downstream Target Gene of Basic Helix-Loop-Helix Transcription Factor MyoD. Molecular and Cellular Biology. 22(20). 7066–7082.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Vanessa Ramírez Breakdown of academic impact, for papers by Feihong Luo Breakdown of academic impact, for papers by Teoman Akçay Breakdown of academic impact, for papers by Brian C. Cooper Breakdown of academic impact, for papers by Shigeo Akira Breakdown of academic impact, for papers by Julie M. Carroll Breakdown of academic impact, for papers by Cristiana Libardi Miranda Furtado Breakdown of academic impact, for papers by Giovanna Municchi Breakdown of academic impact, for papers by Talat Mushtaq Breakdown of academic impact, for papers by Keshav Kumar Gupta